Cervical Intraepithelial Neoplasia
Conditions
Keywords
Cervix, CIN, HPV, Triage, ASCUS/LSIL, Pap Smear, HPV Test
Brief summary
Approximately 65 million Pap smears are performed each year in the United States. The vast majority of results are negative (no abnormality identified) but about 5 percent to 8 percent are reported as abnormal. Most low-grade changes regress spontaneously; only a minority of such lesions would progress to a cancer precursor without treatment. However, there is no way to determine morphologically which patients are at risk or progression. Therefore, both high- and low-grade lesions were often managed with colposcopy and directed biopsy. Epidemiologic, virologic and molecular studies have clearly demonstrated that human papillomavirus (HPV) is the central cause of cervical cancer. The motivation for the Atypical squamous cells of undetermined significance (ASCUS)- Low grade squamous intraepithelial lesion (LSIL) Triage Study (ALTS) trial was to use the information we have gained about the role of HPV to design better treatment and prevention strategies to reduce the burden of cervical cancer and its precursors. ALTS consisted of three management strategies: (1) immediate colposcopy of all women; (2) repeat cytology with colposcopy only if the results show a high grade lesion; and (3) HPV testing and repeat cytology in combination, with referral to colposcopy if either the HPV test is positive or the cytology shows a high grade lesion. Four Clinical Centers University of Alabama, Birmingham Alabama (AL); Magee-Womens Hospital, Pittsburgh Pennsylvania (PA); University of Oklahoma, Oklahoma City OK; and University of Washington, Seattle Washington (WA) enrolled approximately 5,000 women with recent diagnosis of ASCUS or LSIL. Participants were followed at six month intervals for a total of 2 years. The ALTS database and ALTS specimens continue to be a valuable research resource in studies of cervical cancer precursors, screening tests, visual assessment of the cervix and investigation of biomarkers.
Detailed description
Approximately 65 million Pap smears are performed each year in the United States. The vast majority of results are negative (no abnormality identified) but about 5 percent to 8 percent are reported as abnormal. Most low-grade changes regress spontaneously; only a minority of such lesions would progress to a cancer precursor without treatment. However, there is no way to determine morphologically which patients are at risk of progression. Therefore, both high- and low-grade lesions were often managed with colposcopy and directed biopsy. It was anticipated that determining alternative management strategies would yield important potential benefits including fewer medical complications from over treatment, reduced patient anxiety associated with referral for cytologic abnormalities, as well as cost savings. Epidemiologic, virologic and molecular studies have clearly demonstrated that human papillomavirus (HPV) is the central cause of cervical cancer. The motivation for the ALTS trial was to use the information we have gained about the role of HPV to design better treatment and prevention strategies to reduce the burden of cervical cancer and its precursors. ALTS consisted of three management strategies: (1) immediate colposcopy of all women; (2) repeat cytology with colposcopy only if the results show a high grade lesion; and (3) HPV testing and repeat cytology in combination, with referral to colposcopy if either the HPV test is positive or the cytology shows a high grade lesion. Four Clinical Centers University of Alabama, Birmingham AL; Magee-Womens Hospital, Pittsburgh PA; University of Oklahoma, Oklahoma City OK; and University of Washington, Seattle WA - enrolled approximately 5,000 women with recent diagnosis of ASCUS or LSIL. Participants were followed at six month intervals for a total of 2 years. The main results from ALTS showed that for women with ASCUS cytology, HPV triage was at least as safe as universal immediate colposcopy in the detection of high-grade lesion and would allow approximately half of women to return to routine follow up without additional procedures (colposcopy). No efficient triage strategy was identified for women with LSIL cytology. The ALTS database and ALTS specimens continue to be a valuable research resource in studies of cervical cancer precursors, screening tests, visual assessment of the cervix and investigation of biomarkers.
Interventions
Pap test
Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test
Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
Sponsors
Study design
Masking description
Computer random assignment to HPV testing (HC2), cytology (ThinPrep), or immediate colposcopy.
Eligibility
Inclusion criteria
* Inclusion Criteria: * Diagnosis of atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) * 18 years or older * Able to give informed consent with reasonable likelihood of follow-up
Exclusion criteria
* Previous Hysterectomy * History of excisional or ablative treatment of cervix, such as laser treatment, radiation therapy, cauterization (burning), freezing or surgery such as cone biopsy or loop electrosurgical excision procedure (LEEP). * Already known to be pregnant * Already known to be human immunodeficiency virus (HIV) positive (HIV may negatively affect the clinical history of human papillomavirus (HPV), making triage less appropriate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III) | up to 2 years | A cervical exam, pap test, human papilloma virus (HPV) deoxyribonucleic acid (DNA) test, and/or colposcopy was performed to detect whether or not a participant had CINIII. CINIII is defined as moderate or severe dysplasia or abnormal cells located on the cervix that can lead to cancer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Cumulative Detection of Clinical Center Histologically Confirmed Cervical Intraepithelial Neoplasia 2 (CIN2) and Above (High Grade Lesion) Over the 2 Years of the Trial. | up to 2 years | Cumulative detection of CIN2 and above was assessed by pathologists who reviewed specimens from cervical pelvic exams (i.e. thin prep pap test, Human papillomavirus (HPV) Deoxyribonucleic acid (DNA) test, and/or colposcopy). Pathologists graded the specimens from CIN2 (moderate grade lesion) to CIN3 (high grade lesion). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cytology Referred to colposcopy if cytology is high grade
Thinprep: Pap test | 1,839 |
| Human Papillomavirus (HPV) Referred to colposcopy if cytology is high grade or HPV +
Hybrid capture 2: Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test | 1,385 |
| Colposcopy All refer to colposcopy
Colposcopy: Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva. | 1,836 |
| Total | 5,060 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 425 | 229 | 351 |
Baseline characteristics
| Characteristic | Cytology | Human Papillomavirus (HPV) | Colposcopy | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 103 Participants | 63 Participants | 99 Participants | 265 Participants |
| Age, Categorical >=65 years | 7 Participants | 9 Participants | 8 Participants | 24 Participants |
| Age, Categorical Between 18 and 65 years | 1729 Participants | 1313 Participants | 1729 Participants | 4771 Participants |
| Age, Continuous | 27.22 years STANDARD_DEVIATION 8.73 | 28.28 years STANDARD_DEVIATION 9.62 | 27.24 years STANDARD_DEVIATION 8.9 | 27.52 years STANDARD_DEVIATION 9.05 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 81 Participants | 65 Participants | 84 Participants | 230 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1754 Participants | 1317 Participants | 1751 Participants | 4822 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 4 Participants | 3 Participants | 1 Participants | 8 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 41 Participants | 27 Participants | 40 Participants | 108 Participants |
| Race (NIH/OMB) Asian | 48 Participants | 57 Participants | 65 Participants | 170 Participants |
| Race (NIH/OMB) Black or African American | 559 Participants | 427 Participants | 569 Participants | 1555 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 11 Participants | 9 Participants | 16 Participants | 36 Participants |
| Race (NIH/OMB) White | 1180 Participants | 865 Participants | 1146 Participants | 3191 Participants |
| Region of Enrollment United States | 1839 Participants | 1385 Participants | 1836 Participants | 5060 Participants |
| Sex: Female, Male Female | 1839 Participants | 1385 Participants | 1836 Participants | 5060 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 1,839 | 0 / 1,385 | 0 / 1,836 |
| other Total, other adverse events | 0 / 1,839 | 0 / 1,385 | 0 / 1,836 |
| serious Total, serious adverse events | 0 / 1,839 | 0 / 1,385 | 0 / 1,836 |
Outcome results
Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III)
A cervical exam, pap test, human papilloma virus (HPV) deoxyribonucleic acid (DNA) test, and/or colposcopy was performed to detect whether or not a participant had CINIII. CINIII is defined as moderate or severe dysplasia or abnormal cells located on the cervix that can lead to cancer.
Time frame: up to 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cytology | Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III) | 10.93 percentage of participants |
| Human Papillomavirus (HPV) | Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III) | 10.25 percentage of participants |
| Colposcopy | Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III) | 10.84 percentage of participants |
Percentage of Participants With Cumulative Detection of Clinical Center Histologically Confirmed Cervical Intraepithelial Neoplasia 2 (CIN2) and Above (High Grade Lesion) Over the 2 Years of the Trial.
Cumulative detection of CIN2 and above was assessed by pathologists who reviewed specimens from cervical pelvic exams (i.e. thin prep pap test, Human papillomavirus (HPV) Deoxyribonucleic acid (DNA) test, and/or colposcopy). Pathologists graded the specimens from CIN2 (moderate grade lesion) to CIN3 (high grade lesion).
Time frame: up to 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cytology | Percentage of Participants With Cumulative Detection of Clinical Center Histologically Confirmed Cervical Intraepithelial Neoplasia 2 (CIN2) and Above (High Grade Lesion) Over the 2 Years of the Trial. | 16.69 percentage of particpants |
| Human Papillomavirus (HPV) | Percentage of Participants With Cumulative Detection of Clinical Center Histologically Confirmed Cervical Intraepithelial Neoplasia 2 (CIN2) and Above (High Grade Lesion) Over the 2 Years of the Trial. | 18.12 percentage of particpants |
| Colposcopy | Percentage of Participants With Cumulative Detection of Clinical Center Histologically Confirmed Cervical Intraepithelial Neoplasia 2 (CIN2) and Above (High Grade Lesion) Over the 2 Years of the Trial. | 20.75 percentage of particpants |